Glioblastoma Multiforme
Conditions
Keywords
Glioblastoma Multiforme, GBM, Btk,, CLL, Chronic Lymphocytic Leukemia, NK, Natural Killer (Cells), ORR, Overall Response Rate, OS, Overall Survival, RANO, Response Assessment in Neuro-oncology (Criteria), RCI, Reliale Change Index (methodology)
Brief summary
A Phase 1b/2, Multicenter, Open-Label Study of ACP-196 in Subjects with Recurrent Glioblastoma Multiforme (GBM)
Detailed description
A Phase 1b/2, multicenter, open-label study was designed to evaluate the efficacy and safety of acalabrutinib in subjects with recurrent glioblastoma multiforme (GBM) who had progressed after one or two prior systemic treatment regimens.
Interventions
DRUGACP-196
Cohort 1: ACP-196 200 mg (PO) twice per day (BID) Cohort 2: ACP-196 400 mg (PO) once per day (QD).
Sponsors
Acerta Pharma BV
Study design
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Men and women ≥18 years of age * Histologically confirmed GBM at first or second recurrence after concurrent or adjuvant chemotherapy or radiotherapy (must have received temozolomide). * Radiographic demonstration of disease progression by MRI following prior therapy. * Measurable disease (bidimensional) as defined by the RANO criteria, with a minimum measurement of 1 cm in longest diameter on MRI performed within 21 days of first dose of acalabrutinib; MRI must have been obtained ≥4 weeks after any salvage surgery after first or second relapse. * Stable or decreasing dose of corticosteroids ≥5 days before baseline MRI (at study entry). * On a stable dose of any required therapy (such as anticonvulsant medication for subjects to be enrolled into the Phase 1b portion), for ≥3 weeks before the first dose of acalabrutinib. * Eastern Cooperative Oncology Group (ECOG) performance status of ≤2. * Life expectancy ≥ 12 weeks. * Completion of all prior anticancer therapy before first ACP-196 dose. * Need to have recovered (i.e., Grade ≤1 or baseline) from AEs associated with prior cancer therapy. Note: Subjects with Grade ≤2 neuropathy or Grade * 2 alopecia are an exception, and may qualify for the study.
Exclusion criteria
* Three or more prior lines of systemic therapy for GBM. * Prior malignancy (other than GBM), except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer from which the subject has been disease free for ≥2 years. Any cases of prior malignancy allowed on study are to be approved by the study medical monitor. * Significant cardiovascular disease. * Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel, symptomatic inflammatory bowel disease, partial or complete bowel obstruction, or gastric restrictions and bariatric surgery, such as gastric bypass. * Evidence of bleeding diathesis or coagulopathy. * Requires urgent palliative intervention for primary disease * Requires treatment with a strong CYP3A4 inhibitor.. * History of stroke or clinically significant intracranial hemorrhage within 6 months before first dose of study drug. * Breastfeeding or pregnant. * Subjects previously treated with bevacizumab (Avastin)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Assessment of Tumor Status for Overall Response Rate With Use of RANO Criteria. | On Cycle 3 Day 1, Cycle 4 Day 1 (4 weeks after Cycle 3 Day 1 scan to evaluate for response stability), then on Day 1 of every other cycle (every 8 weeks) thereafter (e.g., Cycle 6 Day 1, Cycle 8 Day 1) | To evaluate the efficacy of acalabrutinib monotherapy in subjects with recurrent GBM based on overall response rate (ORR) per the Response Assessment in Neuro-oncology (RANO) criteria. Responses are either complete response (CR) or partial response (PR) by RANO. |
Countries
United States
Contacts
STUDY_DIRECTORAcerta Clinical Trials
1-888-292-9613; acertamc@dlss.com
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Cohort 1 Acalabrutinib 200mg administered orally (PO) twice daily (BID). | 15 |
| Cohort 2 Acalabrutinib 400mg PO (QD). | 9 |
| Total | 24 |
Baseline characteristics
| Characteristic | Cohort 1 | Total | Cohort 2 |
|---|---|---|---|
| Age, Continuous | 58.7 Year STANDARD_DEVIATION 6.74 | 53.8 Year STANDARD_DEVIATION 11.64 | 45.7 Year STANDARD_DEVIATION 13.84 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants | 1 Participants | 1 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 15 Participants | 22 Participants | 7 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 1 Participants | 1 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 1 Participants | 1 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 1 Participants | 2 Participants | 1 Participants |
| Race (NIH/OMB) White | 13 Participants | 21 Participants | 8 Participants |
| Region of Enrollment United States | 15 Participants | 24 Participants | 9 Participants |
| Sex: Female, Male Female | 7 Participants | 11 Participants | 4 Participants |
| Sex: Female, Male Male | 8 Participants | 13 Participants | 5 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 12 / 15 | 7 / 9 |
| other Total, other adverse events | 15 / 15 | 9 / 9 |
| serious Total, serious adverse events | 6 / 15 | 4 / 9 |
Outcome results
Primary
Assessment of Tumor Status for Overall Response Rate With Use of RANO Criteria.
To evaluate the efficacy of acalabrutinib monotherapy in subjects with recurrent GBM based on overall response rate (ORR) per the Response Assessment in Neuro-oncology (RANO) criteria. Responses are either complete response (CR) or partial response (PR) by RANO.
Time frame: On Cycle 3 Day 1, Cycle 4 Day 1 (4 weeks after Cycle 3 Day 1 scan to evaluate for response stability), then on Day 1 of every other cycle (every 8 weeks) thereafter (e.g., Cycle 6 Day 1, Cycle 8 Day 1)
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Cohort 1 | Assessment of Tumor Status for Overall Response Rate With Use of RANO Criteria. | 1 Participants |
| Cohort 2 | Assessment of Tumor Status for Overall Response Rate With Use of RANO Criteria. | 1 Participants |